Alpha 2.0
Login Register
» Articles » PMID: 37330134

Tenapanor for the Treatment of Hyperphosphatemia in Japanese Hemodialysis Patients: A Randomized Phase 3 Monotherapy Study With an Up-titration Regimen

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2023 Jun 17
PMID 37330134
Authors
Masafumi Fukagawa
Natsuki Urano
Kazuaki Ikejiri
Jun Kinoshita
Kaoru Nakanishi
Tadao Akizawa
Affiliations
Soon will be listed here.
Citing Articles

Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia.

Akizawa T, Urano N, Ikejiri K, Nakanishi K, Fukagawa M Ther Apher Dial. 2025; 29(2):157-169.

PMID: 39829064 PMC: 11879479. DOI: 10.1111/1744-9987.14241.

Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis.

Yu S, Sun J, Guo X Ren Fail. 2024; 46(2):2410389.

PMID: 39351794 PMC: 11445914. DOI: 10.1080/0886022X.2024.2410389.

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.

Nitta K, Itoyama S, Ikejiri K, Kinoshita J, Nakanishi K, Fukagawa M Kidney Int Rep. 2023; 8(11):2243-2253.

PMID: 38025211 PMC: 10658421. DOI: 10.1016/j.ekir.2023.08.003.

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.

Koiwa F, Sato Y, Ohara M, Nakanishi K, Fukagawa M, Akizawa T Sci Rep. 2023; 13(1):19100.

PMID: 37925471 PMC: 10625594. DOI: 10.1038/s41598-023-45080-9.

Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.

Nakayama M, Kobayashi S, Kusakabe M, Ohara M, Nakanishi K, Akizawa T Clin Exp Nephrol. 2023; 28(2):153-164.

PMID: 37910313 PMC: 10808471. DOI: 10.1007/s10157-023-02406-1.